Echosens

Trusts Cathay Capital

1 billion people worldwide suffer from chronic liver diseases: viral hepatitis B and C, fibrosis, cirrhosis, non-alcoholic hepatic steatosis. 2 million people die of these diseases every year.

Until 2001, liver biopsy was the only existing medical technology to diagnose liver disorders. Problem: this technology is invasive as it consists in extracting a small piece of liver to analyze it.

In 2000 Laurent Sandrin presented a thesis on pulse elastography by ultrasound. A surgeon and a radiologist from the Montsouris Institute recommended he apply his research on shear waves and on the measurement of the elasticity of biological tissues to the liver.

Fundamental research has just demonstrated its applications and thus immediately opened a new market: non-invasive liver diagnosis.
The Fibroscan was launched in 2001: through shear waves whose speed depends on the elasticity of the medium through which it passes, it allows the measurement of key health parameters of the liver.

The market remained to be invested. Who better than Cathay to open up the Chinese market to such an innovative French technology?

Who better than Cathay and its two teams in Beijing and Shanghai to understand the strategy of Furui, the Chinese pharmaceutical group listed on the Shenzhen stock exchange which bought Echosens in 2011?

Who better than Cathay and its managers from Paris to New York to explain the Chinese and American market to Laurent Sandrin and his team?

We acquired a 24% stake in April 2015: 24% for 40 million. A minority shareholder but a leader on strategy: alongside an American MedTech fund and a Chinese family office, we unleashed the company’s potential.

A custom-made sales force of 30 people is created in the USA to manage distribution and share the uses of the Fibroscan device with American hospitals: in two years sales increased from 7 to 22 million euros. At the same time in China, a new version of the Fibroscan was launched to make this revolutionary technology, enabling diagnosis and predictions of liver diseases, accessible to hospitals in category 3 (249 cities) and 4 (368 cities). There is no difference between a sick Chinese liver and a sick American liver.

In less than 3 years, the company has built up its leadership thanks to our expansion strategy in Chinese and American markets and to its efficiency and autonomy gains in the field of governance.

Over this period, our IRR reached 36.7% and our performance x 2.45.

Cathay is at the heart of the world’s top 3 economies: without the creativity of the American market and the intelligence of the Chinese market Echosens would have remained a brilliant French research laboratory.

Cathay’s and entrepreneurs’ minds meet in believing in the power of their ideas: understanding entrepreneurs means helping them turn their ideas into businesses for the greatest benefit of all. Why invent a revolutionary method for diagnosing liver disease if not to save as many lives as possible?

Cathay is at the crossroads of global trends transforming markets: the ideas that change the world are not made in China, made in France or made in the USA, they are made in Brains. We are here to connect them to each other and to the markets, through the capital we invest and through our cross-border culture and ecosystem spanning 4 continents.

Cathay Capital

OFFICES & CONTACTS

For all general inquiries, please contact us at [email protected] or call the Paris office at +33 1 42 25 28 00

Paris Office
52 Rue d’Anjou
2nd Floor 75008 Paris FRANCE
Tel: +33 1 42 25 28 00
Fax: +33 1 58 28 52 25
Email: [email protected]

Shanghai Office
3001-3002 Kerry Parkside,
No.1155 Fangdian Road Pudong Shanghai P.R. CHINA
Tel: + 86 21 6888 8069
Fax: + 86 21 6888 8079
Email: [email protected]

Beijing Office
2317-2318, Beijing Kerry Centre,
No.1 Guang Hua Road, Beijing P.R. CHINA
Tel: +86 10 6505 6277
Fax: +86 10 6505 6297
Email: [email protected]

New York Office
150 East 52nd Street, 20th Floor
New York, NY 10022 – 4608 – USA
Tel: +1 212 858 9020
Email: [email protected]

San Francisco Office
Cathay Innovation
101 Mission Street,
Suite 1630
San Francisco, CA 94105, USA
Email: [email protected]

Munich Office
Cathay Capital Advisory GmbH
Theatinerstraße 7
80333 Munich GERMANY
Tel: +49 89 26 20 446 10
Email: [email protected]

Singapore Office
5 Shenton Way,
#22-04, UIC Building,
Singapore 068808
Email: [email protected]

Tel Aviv Office
Cathay Innovation
Hanechoshet St.6
Tel Aviv
Yafo 69710
Email : [email protected]

Cathay Capital Group is a global investment platform specialized in cross-border development with a focus on Northern America, China, Europe and Africa. The group identifies investment opportunities with the potential to impact the world and accompanies portfolio companies in their international expansion through its ecosystem of partners and the local expertise.

RECEIVE OUR NEWSLETTER

FOLLOW US

Copyright © 2020 Cathay Capital | All rights reserved